A compound that is a backup tends to be one step earlier than the lead, at least through PhII. It makes sense that Organon would be establishing the safety of the backup as they test the efficacy of the lead.
Org26576 is a Cortex compound--or to be more precise, I know that it falls under the same partnership agreement. It is probably one of those licensed from Cortex, though there could be something like the agreement with Servier, where Servier had to throw most of its compounds into the same pot.
BTW--someone asked if there could be an 'out' of the Organon deal like there was one out of the Servier deal. If there was one, Cortex would have taken it.
Ronald Duman, Organon Inc., Influence of Org 2448 and Org 26576 on Neurogenesis in Adult Hippocampus, 1 year, $221,160; National Alliance for Research on Schizophrenia and Depression, Proliferation and Survival of Glia: Regulation by Stress and Antidepressants, 1 year, $100,000
News 
Market Data 
Discover 
AI
